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Thephospho-site adapterprotein 14-3-3 binds to targetproteinsat aminoacid sequences
matching the consensus motif Arg-X-X-Ser/Thr-X-Pro, where the serine or threonine
residue is phosphorylated and X is any amino acid. The dual-specificity phosphatase
CDC25B, which is involved in cell cycle regulation, contains five 14-3-3 binding motifs,
but 14-3-3 preferentially binds to themotif at Ser309 inCDC25B1 (orSer323 inCDC25B3).
In the present study, we demonstrate that amino acid residues C-terminal to the 14-3-3
binding motif strongly affect the efficiency of 14-3-3 binding. Alanine substitutions at
residues downstream of the Ser309motif dramatically reduced 14-3-3 binding, although
phosphorylation of Ser309was unaffected.We also observed that binding of endogenous
14-3-3 to mutant CDC25B occurred less efficiently than to the wild type. Mutants to
which 14-3-3 cannot bind efficiently tend to be located in the nucleus, although not as
specifically as the alanine substitution mutant of Ser309. These results indicate that
amino acid sequences C-terminal to the consensus binding site have an important
role in the efficient binding of 14-3-3 to at least CDC25B, which may partly explain
why some consensus sequences are inactive as 14-3-3 binding sites.
Key words: 14-3-3, CDC25B, cell cycle, phosphorylation, subcellular localization.
Abbreviations: CDK, cyclin-dependent kinase; GST, glutathione-S-transferase; MAPKAP, mitogen-activated
protein kinase–activated protein; MK2, MAPKAP kinase 2; NLS, nuclear localization signal.
The eukaryotic cell cycle progresses through successive
cycles of activation and inactivation of cyclin-dependent
kinases (CDKs) that are complexed with cyclins. The
activities of these complexes are regulated via several
mechanisms, including inhibition of CDK by small proteins
(e.g., p16, p21, and p27), inhibitory phosphorylation by
Wee1/Myt1 kinases at the ATP binding site of CDK, and
activation of dephosphorylation by CDC25 dual-specificity
phosphatases.
Three CDC25 phosphatases have been identified in
mammalian cells, CDC25A, CDC25B, and CDC25C (1).
The first CDC25 phosphatase gene to be identified was
that encoding CDC25C, which dephosphorylates phos-
pho-Tyr15 of CDK1 (previously phosphorylated by Wee1
kinase) to promote the G2 to M phase transition (2, 3).
Studies using cultured mammalian cells have suggested
that CDC25A plays a role in the G1 to S phase transition
by activating CDK2/cyclin E (4, 5), and that CDC25B and
CDC25C function in M phase entry by activating and main-
taining CDK1:cyclin B activity during the M phase (6–9).
Recent reports provided evidence that CDC25A also
plays an important role in the G2 to M phase transition,
thus indicating that CDC25A regulates all cell cycle stages
(10, 11). However, mice depleted of CDC25C by gene
targeting develop normally and become fertile adults
(12), and CDC25B knockout mice are born essentially
healthy, although the females are sterile because of a
defect in oogenesis (13). A recent report confirmed that
mice lacking both the CDC25B and CDC25C genes are
born healthy and that cells derived from these mice not
only undergo normal entry to the M phase but also exhibit
no checkpoint defects (14). Therefore, CDC25B and
CDC25C are not essential for mouse development and
for DNA damage checkpoints.
CDC25 proteins are CDK activators and, as a result,
may comprise important cell cycle checkpoints (15–17).
When the cell cycle checkpoint kinase CHK1 or CHK2 is
activated by genotoxic stress, it phosphorylates several
serine or threonine residues in CDC25A, which leads to
the ubiquitin-proteasome pathway-mediated degradation
of CDC25A that accompanies cell cycle arrest at the G1,
G2, or intra-S phase (10, 17). CDC25B and CDC25C, as
well as CDC25A, are good substrates for CHK1 and CHK2
in vitro (18–20). CDC25B overexpression overrides the G2
checkpoint after ionizing radiation and other genotoxic
stresses, and overproduction of a non-phosphorylated
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mutant form of CDC25C partially overrides the G2
checkpoint (21–24).
One of the phospho-site adapter proteins, 14-3-3,
appears to be centrally involved in the CDC25 function,
especially in terms of checkpoint function (15, 22–25).
CHK1 and CHK2 [and very recently mitogen-activated
protein kinase-activated protein (MAPKAP) kinase 2
(MK2)] have been shown to phosphorylate CDC25B and
CDC25C at phosphorylation sites containing the 14-3-3
consensus binding sequence (23, 24, 26). The binding of
14-3-3 to CDC25B or CDC25C may recruit these phospha-
tases to the cytoplasm from the nucleus and help to retain
them there, thus preventing CDK1 activation in the
nucleus (27–30). However, CDC25 phosphorylation by
CHK1 or CHK2 down-regulates its phosphatase activity,
in both 14-3-3 binding–dependent and –independent
manners (31–33). At this point, the precise role of
CDC25 binding to 14-3-3 in the normal cell cycle and its
checkpoints remains to be defined.
We previously reported that 14-3-3b and 14-3-3e can
bind to Ser309 phosphorylation site in CDC25B1, and
that the single phosphorylation at Ser309 is sufficient to
sustain the binding of the b and e 14-3-3 isoforms (30). In
the present study, we further examined the importance of
14-3-3 binding in the regulation of CDC25B. We studied
binding to CDC25B of other 14-3-3 isoforms, such as 14-3-
3g, Z, y, which is also called t, and z and found that they
bind primarily to the Ser309 site. Furthermore, our results
reveal major roles not only for the amino acids in the
Ser309 consensus site but also for the amino acids sur-
rounding the consensus site in efficient 14-3-3 binding.
EXPERIMENTAL PROCEDURES
Cell Culture and Transformation—HEK293, Cos-7, and
HeLa cells (American Type Culture Collection strains
CRL-1573, CRL-1651, and CCL-2, respectively) were
grown in Dulbecco’s Modified Eagle’s Medium supplemen-
ted with 10% fetal bovine serum, 100 mg/ml penicillin,
100 U/ml streptomycin, and 50 mg/ml M-Plasmocin
under a humidified atmosphere of 5% CO2. Fetal bovine
serum, penicillin, and streptomycin were from Sigma
(St. Louis, MO, USA), and M-Plasmocin from Invivogen
(San Diego, CA, USA). For the transformation of
HEK-293 and Cos-7 cells, appropriate amounts of DNA
were transfected with FuGENE6 (Roche Diagnostics,
Indianapolis, IN, USA). HeLa cells were transfected
with LipofectAMINE2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s recommendation.
Plasmid Construction—Plasmids encoding N-terminal
double FLAG-tagged CDC25B1, and N-terminal double
myc-tagged 14-3-3b, e, and s were constructed as described
previously (30). For the isolation of the other 14-3-3 sub-
types, the coding regions were amplified by PCR using
specific primers for 14-3-3g, Z, y, and z. Each amplified
fragment was subcloned into a modified pEF6-mycHisB
vector (Invitrogen) such that a double Myc-tag was
encoded at each N-terminus. The sequences of these pri-
mers are shown in Table 1. Human CHK1 and CHK2 were
provided by Steve Elledge of Harvard Medical School.
Human MK2 cDNA was purchased from Open Biosystems
(Huntsville, AL, USA). All were amplified with specific
primers (Table 1) and subcloned into modified pEF6-
mycHisB such that a double HA tag was encoded at the
N- or C-terminus and a 6·His tag was encoded at the
C-terminus. The GST-CDC25B peptide expression plasmid
was constructed by PCR amplification of the CDC25B gene,
digestion of the PCR product with NcoI and XhoI, and
ligation into the pGEX-KG vector (34). The primers used
to amplify CDC25B are shown in Table 1.
Site-Directed Mutagenesis—PCR-based site-directed
mutagenesis with complementary oligonucleotide pairs
was used to insert alanine point mutations in CDC25B,
and to place a BamHI restriction site between Leu319
and Lys320 of CDC25B. The sequence of one strand of
each primer pair is shown in Table 2.
Antibodies—Antisera against a phospho-Ser309 peptide
(23) and the FLAG tag (35) were raised as described and
affinity purified. Anti-myc and anti-HA antibodies were
from Cell Signaling (Beverly, MA, USA), anti-GST
Table 1. PCR primers used for amplification and construction of tagged proteins.
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serum from Amersham Biosciences (Piscataway, NJ,
USA), and anti-FLAG M2-beads from Sigma.
Preparation of Cell Extracts, Immunoprecipitation, and
Immunoblotting—Crude cell extracts were prepared as
described previously (30). Cells were collected by scraping,
washed in ice-cold phosphate-buffered saline (PBS), and
lysed with immunoprecipitation (IP) buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40, 5 mM
EGTA, and 1 mM EDTA) supplemented with protease
and phosphatase inhibitor mixes as described previously
(30). Cell extracts were centrifuged at 15,000 · g for 10 min
at 4C, the supernatant fractions were collected, and the
protein concentrations were determined by the Bradford
method (Bio-Rad, Richmond, CA, USA) (36). For immuno-
precipitation, typically 500 mg of protein was mixed with
anti-FLAG M2-agarose beads or 2 mg of anti-myc mono-
clonal antibodies followed by protein G-Sepharose beads
(Amersham Biosciences). Crude cell extracts or immuno-
precipitates were subjected to immunoblotting using rabbit
polyclonal anti-FLAG antibodies (for CDC25B), mouse
monoclonal anti-myc antibodies (for 14-3-3), or mouse
monoclonal anti-HA antibodies (for kinases).
Protein Purification—Protein kinases were prepared
from cDNA-transfected Cos-7 cells. Typically, 8 · 105
Cos-7 cells in a 6-cm dish received 4 mg of plasmid DNA
with FuGENE6. After 24 h, the cells were collected,
washed with PBS, and lysed with EDTA-free IP buffer
supplemented with a 1:100 dilution of FOCUS Protease
Arrest (EMD Biosciences, San Diego, CA, USA), 20 mM
p-nitrophenyl phosphate, 20 mM NaF, and 20 mM b-
glycerophosphate. To purify the kinases, Ni2+-charged
immobilized metal-chelating Sepharose beads (Amersham
Biosciences) were added to the cell extracts containing
1.5 mg protein, and the protein-bound beads were used
directly in kinase assays. GST-tagged proteins were
expressed in Escherichia coli BL21 (DE3) cells transformed
with the appropriate cDNA plasmid constructs.
Expression was induced with 0.4 mM isopropyl-b-D-
thiogalactopyranoside, and proteins were purified with
glutathione–Sepharose beads (Amersham Biosciences).
Indirect Immunofluorescence Microscopy—Indirect
immunofluorescence analysis was performed as described
previously (30, 37). Transfected HEK293 cells were fixed
with 3.7% formaldehyde and then permeabilized with 0.5%
Triton X-100. Expressed CDC25B proteins were detected
with rabbit polyclonal anti-FLAG antibodies, followed by
AlexaFluor 594– or 488–conjugated goat anti-rabbit IgG
(Molecular Probes, Eugene, OR, USA), and expressed 14-
3-3 was detected with mouse monoclonal anti-Myc antibo-
dies and AlexaFluor 488–conjugated goat anti-mouse IgG.
Nuclei were stained with 40,6-diamino-2-phenylindole
(Sigma).
RESULTS
All Seven Isoforms of 14-3-3 Bind to CDC25B—We
previously showed that 14-3-3 isoforms b, e, and s bind
efficiently to CDC25B, with the b and e isoforms binding
preferentially to the 14-3-3 binding motif at Ser309
(309 site), and the s isoform binding preferentially to
the motif at Ser216 (216 site) (30). In the present study,
we analyzed the binding properties of four additional
isoforms of 14-3-3. The genes for the g, Z, y, and z isoforms
were amplified by PCR and expressed in HEK293 cells.
Each 14-3-3 isoform was co-expressed with CDC25B,
isolated, and analyzed as to its interaction with
CDC25B. As shown in Fig. 1, all the14-3-3 isoforms were
able to interact with CDC25B. CDC25B was detected in
immunoprecipitates of all the 14-3-3 isoforms (Fig. 1, upper
panel), and all the 14-3-3 isoforms were recovered in the
CDC25B co-immunoprecipitates (Fig. 1, second panel).
Taking the protein expression levels into account, the
14-3-3e, s, and z isoforms appeared to bind more weakly
to CDC25B than did the other 14-3-3 isoforms (Fig. 1,
second and fourth panels).
As we reported previously (30), CDC25B has five
14-3-3 consensus binding motifs (Fig. 2A). Here, we exam-
ined the CDC25B binding site preference of each 14-3-3
isoform using co-transfection with plasmids encoding
various CDC25B mutants. Five of these mutants contained
Table 2. Sequences of primer pairs used for PCR-based
site-directed mutagenesis of CDC25B.















Fig. 1. Binding of 14-3-3 subtypes to CDC25B. HEK293 cells
(1.4 · 106 cells per 35-mm plate) were transfected with 3 mg of
FLAG-tagged CDC25B DNA and 0.6 mg of myc-tagged 14-3-3
DNA. The cells were collected 24 h after transfection, and cell
extracts were prepared. The cell extracts were either subjected
to Western blotting to visualize protein expression or further pro-
cessed for immunoprecipitation with anti-FLAG or anti-myc anti-
bodies to analyze binding. Upper panel: IP with anti-myc (14-3-3),
followed by IB with anti-FLAG (CDC25B); second panel: IP with
anti-FLAG (CDC25B), followed by IB with anti-myc (14-3-3).
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single-site Ser!Ala substitutions in one 14-3-3 binding
motif (e.g., mutant Ser309Ala). In addition, the 309Ser
mutant contained Ser!Ala substitutions at all possible
binding sites except site 309, and the 5SerAla mutant
contained Ser!Ala substitutions at all five putative bind-
ing sites.
CDC25B immunoprecipitates were recovered from cells
co-transfected with the 14-3-3 and mutant CDC25 genes,
and 14-3-3 was detected on Western blots. All 14-3-3 iso-
forms except 14-3-3s were found to bind preferentially to
site 309 (Fig. 2B), as shown previously (30). Although sub-
stantial binding of 14-3-3y to the Ser309Ala mutant did
occur, comparison with the other single-site mutations
revealed that 14-3-3y bound preferentially to site 309.
These results are summarized in Fig. 2C.
We examined the effect of co-transfection with 14-3-3
isoforms on the subcellular localization of CDC25B.
Previously, we found that the binding of 14-3-3 at site
309 caused CDC25B to move from the nucleus to the
cytoplasm (30). In the present study, we found that
14-3-3 isoforms that preferentially bound at site 309
caused CDC25B to be exported from the nucleus to the
cytoplasm, and that isoforms that bound weakly or non-
preferentially to site 309 did not have such an effect
(Fig. 2D). The 14-3-3y isoform, which binds preferentially
to site 309, exhibited a mobilizing effect on the 309Ser
mutant (data not shown), consistent with the results of
the binding analysis above.
Mutations Near Ser309 of CDC25B Interfere with 14-3-3
binding—The effects of co-transfection with 14-3-3 on the
cytoplasmic distribution of CDC25B indicated that 14-3-3
binding at site 309 may have masked the nuclear localiza-
tion signal (NLS) sequence of CDC25B, which begins about
ten residues downstream of the binding site (Fig. 3A).
We therefore conducted experiments to determine the
effect of an increased distance between Ser309 and the
NLS sequence. Lys320 is the first residue of the bipartite
NLS sequence in CDC25B. To enable the in-frame
insertion of additional amino acids, we initially used muta-
genesis to introduce a BamHI site between residues
319 and 320. The BamHI recognition sequence resulted
in the insertion of Gly–Ser (GS) dipeptide immediately
before Lys320 (Fig. 3A). We found, however, that this
GS insertion abolished 14-3-3 binding to CDC25B, despite
the fact that phosphorylation at site 309 was detected with
phospho-Ser309 antibodies (Fig. 3B).
These results were intriguing because there have been
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Fig. 2. CDC25B binding site preferences of 14-3-3 subtypes.
FLAG-tagged CDC25B mutants with Ser!Ala substitutions at
possible 14-3-3 binding sites (30) were co-transfected with each
14-3-3 subtype, as described in Fig. 1. Cell extracts were prepared
24 h after transfection and then immunoprecipitated with anti-
FLAG-agarose beads to recover the CDC25B mutant proteins.
Recovered CDC25B and co-immunoprecipitated 14-3-3 were
detected by Western blotting. A: Possible 14-3-3 consensus binding
sites and their amino acid sequences. B: Isoforms of 14-3-3 recovered
with anti-FLAG-agarose beads. The bottom panel indicates a
typical result of expression of co-transfected CDC25B mutants.
C. Summary of the results shown in B. ++, strong signal; +, moderate
signal; –, discernible after long exposure; –, no signal. D. Subcellular
localization of wild-type CDC25B upon co-expression with
14-3-3 subtypes. Cover slips in 35-mm plates were seeded with
2 · 105 HEK293 cells. After 2 days, the cells were transfected
with myc-tagged 14-3-3 subtypes in combination with FLAG-tagged
wild-type CDC25B. The cells were fixed 24 h after transfection, and
the subcellular localization of CDC25B was determined by staining
with anti-FLAG antibodies. More than 200 cells were examined.
The data shown are the averages of three independent experiments.
Bars = standard deviation.
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to the 14-3-3 binding site affect the interaction between
14-3-3 and its target proteins. We further examined this
phenomenon by introducing single alanine point mutations
at residues 304 to 319 of CDC25B, and then co-transfecting
the resulting mutants and 14-3-3b (indicated by bold italic
letters in Fig. 3A). Surprisingly, all of the tested point
mutations except Cys312Ala and Leu319Ala caused a
diminished interaction with 14-3-3 (Fig. 3C). The results
clearly demonstrate that the hydrophobic amino acid
region from Val315 to Ile318 seems to be important for
14-3-3 binding (Fig. 3D and depicted by asterisks in
Fig. 3A). Pro311 of CDC25B, which is part of the 14-3-3
binding consensus sequence, also appeared to be important
for 14-3-3 binding. Thus, alterations in the amino acids
near the core consensus sequence of site 309 of CDC25B
negatively affected its ability to bind to 14-3-3.
Ser309 Phosphorylation by Several Candidate
Kinases—To study the in vivo phosphorylation of Ser309
in these mutants, we transfected some of the mutant
CDC25B genes, and the mutant proteins were recovered
and assayed for phosphorylation at Ser309. As shown in
Fig. 4A, phosphorylation of Ser309 occurred in all of the
mutants expressed in HEK293 cells, except for the
Pro317Ala mutant expressed in Cos-7 cells.
Several kinases that phosphorylate Ser309 of CDC25B1
(or Ser323 of CDC25B3) have been reported. We attempted
to determine which kinases could phosphorylate the
CDC25B mutants. We expressed candidate kinases
Fig. 3. Binding of 14-3-3b to
CDC25B mutants with sub-
stitutions near Ser309. CDC25B
mutants containing point
substitutions near Ser309 were
co-transfected with 14-3-3b, and
CDC25B mutant proteins were iso-
lated with anti-FLAG-agarose beads
as described in Fig. 2.
CDC25B-bound 14-3-3b was identi-
fied with an anti-myc antibody. A.
Amino acid sequence from Leu304
to Arg321. Ser309 is denoted by an
outlined letter S. A BamHI
site (GGATCC), which encodes Gly–
Ser, was inserted between Leu319
and Lys320. Lys320 is the N-terminal
end of the NLS sequence in CDC25B,
which is indicated by an arrow. Bold
italic letters indicate amino acids
changed to Ala to analyze 14-3-3
binding, the results of which are
depicted in (C) and (D). Asterisks
indicate the hydrophobic amino acid
stretch (see text). The GS insertion
mutant (+ GS in B) and a series of
point mutants (C) of CDC25B were
analyzed as to their binding to 14-3-
3b and the phosphorylation of
Ser309, which was determined with
anti-phospho-Ser309 antibodies. The
efficiency of 14-3-3b binding to each
CDC25B mutant relative to wild-type
CDC25B was calculated from the
data presented in (C) and is depicted
in (D). The data shown are the
averages of three independent
experiments. Bars = standard
deviation.
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CHK1 (18), CHK2 (19) and MK2 (26) in Cos-7 cells and
then recovered the kinases by immunoprecipitation. For
the preparation of MK2, an upstream kinase, mitogen-
activated protein kinase kinase kinase 6 (MKK6) and
MK2 were co-transfected, and the expressed MK2 was
immunoprecipitated. An in vitro phosphorylation assay
indicated that the three kinases could phosphorylate
GST-tagged CDC25B mutant peptides (Fig. 4B), the
results being similar to those obtained in vivo (Fig. 4A).
The kinases phosphorylated all of the mutant peptides
with similar efficiency, with the exception of the Pro317Ala
mutant, consistent with the results shown in Fig. 4A.
These results demonstrate that Ser309 of CDC25B can
be phosphorylated by several kinases.
Binding of Endogenous 14-3-3 to CDC25B Mutants and
Their Subcellular Localization—We examined the binding
of endogenous 14-3-3 to mutant CDC25B proteins. After
transfection to HEK293 cells, CDC25B proteins were
recovered, and the bound 14-3-3 protein was quantitated
using a pan-14-3-3 antibody. Figure 5A shows that the
efficiency of endogenous 14-3-3 binding to mutant
CDC25B was similar to that in the co-expression experi-
ments. Endogenous 14-3-3 bound to wild-type CDC25B
most efficiently and to the 309Ala mutant least efficiently.
A lesser amount of endogenous 14-3-3 was detected with
the 315Ala mutant, which exactly matched the results in
Fig. 3C and D. The phosphorylation of S309 in the I315A
mutant could also be reproduced (compare Figs. 5A and
4A). We examined the subcellular localization of these
mutant CDC25B proteins expressed in cells (Fig. 5B).
The number of cells with CDC25B specifically localized
in the nucleus was higher for mutant CDC25B than for
the wild-type protein. About 72% of the cells exhibited
specific nuclear localization of CDC25B 315Ala mutants,
which was higher than the frequency of nuclear localiza-
tion of wild-type CDC25B (60%). Collectively, amino acid
sequences surrounding the 14-3-3 binding core consensus
site have a strong influence on 14-3-3 binding but subcel-
lular localization of CDC25B can not be simply explained
by 14-3-3 binding.
Finally, the results of this study are summarized in
Table 3.
DISCUSSION
Seven isoforms of 14-3-3 have been identified in mamma-
lian cells. We previously reported that three isoforms, 14-3-
















































































Fig. 4. Phosphorylation of Ser309 in vivo and in vitro by
representative kinases. HEK293 cells (1.4 · 106 cells per
35-mm plate) or Cos-7 cells (2 · 105 cells per 35-mm plate) were
transfected with plasmids carrying FLAG-tagged CDC25B
mutants, and the expressed proteins were immunoprecipitated
with monoclonal anti-FLAG beads. The precipitated proteins
were immunoblotted with anti-FLAG or anti-phospho-Ser309
antibodies (A). His- and HA-tagged kinases were expressed in
Cos-7 cells and recovered as described. The recovered kinases
were incubated with GST-fused CDC25B peptides (wild-type
or mutant), and phosphorylation at Ser309 was determined by
immunoblotting (B).
WT S309A I 315A
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Fig. 5. Binding of endogenous 14-3-3 to CDC25B mutants
and subcellular localization. HEK293 cells were transfected
with plasmids carrying wild type CDC25B or Ala309 or Ala315
mutants, and the expressed proteins were recovered with anti-
FLAG beads. The precipitates were immunoblotted with an anti-
pan 14-3-3 antibody (upper panel), anti-FLAG antibody (second
panel), or anti–phospho-Ser309 antibody (third panel). The expres-
sion of endogenous 14-3-3 and transfected CDC25B is indicated in
the two bottom panels (A). HEK293 cells were transfected with
CDC25B plasmids as in (A), and the subcellular localization of
the expressed CDC25B proteins was determined as in Fig. 2D.
The numbers represent the percentages of cells expressing the
CDC25B protein found exclusively in the nucleus. Three indepen-
dent experiments were performed for each value , and more than
200 CDC25B-expressing cells were counted in each experiment (B).
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binding site for 14-3-3b and e is different from that for 14-3-
3s. Moreover, after binding to 14-3-3b or e but not s,
CDC25B is exported to the cytoplasm. The recently pub-
lished X-ray structure results revealed the following spe-
cific functional and structural features of the 14-3-3s
isoform. First, it usually forms a homodimer. Second, 14-
3-3s possesses a ligand-discriminating, special amino acid
patch on the second ligand-binding surface (38). These
findings may explain the difference in the binding proper-
ties of 14-3-3b and s as to CDC25B.
Here, we evaluated whether four other 14-3-3 subtypes
(g, Z, y/t, and z) also bind to CDC25B and exhibit behavior
similar to that of 14-3-3b. The 14-3-3y/t isoform exhibited
slightly different properties from those of the other
three isoforms in that it bound to other 14-3-3 motifs in
CDC25B in addition to site 309. The 14-3-3z isoform
bound to CDC25B more weakly at Ser309 than did the
other isoforms, except 14-3-3s. These subtle differences
appeared to affect the ability of these isoforms to cause
the transfer of CDC25B from the nucleus to the cytoplasm.
Our results show that six of the seven 14-3-3 subtypes in
mammalian cells behave similarly in terms of CDC25B
binding. The specific function of the 14-3-3s isoform is
unknown.
The typical consensus 14-3-3 binding sequence consists
of Arg-X-X-Ser/Thr-X-P (mode-I) or Arg-X-X-X-Ser/Thr-X-
P (mode-II), where the serine or threonine must be phos-
phorylated (39, 40). In addition to these binding motifs,
14-3-3 also binds to the recently identified mode-III
motif, which consists of (p)S/T-X1–2-COOH at the
C-terminus of several proteins (41). Although the results
of oriented peptide analysis suggest that the Arg-X-X-
(p)Ser/Thr-X-P mode-I motif is sufficient for 14-3-3 bind-
ing, a more complicated situation appears to exist in vivo.
For example, we previously found that CDC25B contains
five 14-3-3 binding motifs, but only three of these are
functional. The principal 14-3-3 binding site is at
Ser309, and the Ser216 site in combination with the
Ser137 or Ser309 site may also be important, especially
for binding to 14-3-3s.
One possible reason for the apparent non-functionality of
certain 14-3-3 binding motifs in vivo may be the lack of
phosphorylation of target Ser/Thr. The results described in
this report suggest another somewhat unexpected expla-
nation. We found that alterations in amino acids
C-terminal to the binding motif at site 309 severely
impaired 14-3-3 binding, indicating that 14-3-3 binding
depends not only on the consensus sequence but also on
its context. Thus, the binding of 14-3-3 may require not
only the presence of the binding motif in its appropriately
phosphorylated form but also the presence of a suitable
sequence C-terminal to the binding site. Substitution
mutations of amino acid residues often disrupt the local
structure of proteins. Therefore, some mutants examined
in this study may harbor a structural change that abolishes
14-3-3 binding. However, Ser309 in each CDC25B mutant,
except Pro317Ala, was efficiently phosphorylated at the
same level as that of the wild-type protein in transfected
cells. These results imply (but do not prove unequivocally)
that a gross structural change should not be introduced by
the mutations. Studies using an oriented peptide library
with a random amino acid sequence placed C-terminal to
the consensus site will be important for confirmation of our
hypothesis.
The specific kinases that phosphorylate Ser309 of
CDC25B have yet to be identified. We examined kinases
that have been reported to phosphorylate this residue, but
they exhibited essentially the same specificity toward
mutated substrates in vitro. All of the tested kinases
required a proline at residue 317 and an arginine at resi-
due 306, although Pro317 was not essential for Ser309
phosphorylation in vivo. The kinase responsible for regu-
lating CDC25B localization must exhibit an appropriate
subcellular localization. In the normal cell cycle,
CDC25B is located in the nucleus, and Ser309 is phos-
phorylated to some degree even in the absence of cellular
injury (23). In view of this, kinases that phosphorylate
Ser309 would also be expected to be located in the nucleus.
Of these kinases, we propose that CHK1 and MK2 may be
suitable for the phosphorylation of Ser309 of CDC25B1,
even in the absence of specific cellular damage, since
they are activated at low levels during DNA replication
and environmental stress, respectively (Ref. 26 and our
unpublished data). It is a matter for further investigation
Table 3. Summary of 14-3-3b binding and Ser309 phosphorylation of each CDC25B mutant.
Name Sequence 14-3-3b Ser309 phosphorylation
Binding (%) in vivo in vitro
WT 304LFRSPSMPCSVIRPILKR321 100 + +
GS LFRSPSMPCSVIRPILGSKR 17 + NT
L304A A- - - - - - - - - - - - - - -KR 70 + –
R306A - -A- - - - - - - - - - - - -KR 23 NT NT
S309A - - - - -A- - - - - - - - - -KR 18 – –
M310A - - - - - -A- - - - - - - - -KR 60 NT NT
P311A - - - - - - -A- - - - - - - -KR 25 NT NT
C312A - - - - - - - -A- - - - - - -KR 103 NT NT
S313A - - - - - - - - -A- - - - - -KR 63 NT NT
V314A - - - - - - - - - -A- - - - -KR 21 + +
I315A - - - - - - - - - - -A- - - -KR 17 + +
R316A - - - - - - - - - - - -A- - -KR 27 + +
P317A - - - - - - - - - - - - -A- -KR 27 + –
I318A - - - - - - - - - - - - - -A-KR 25 + +
L319A - - - - - - - - - - - - - - -AKR 72 + +
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as to whether these kinases phosphorylate this site more
heavily when cells are injured.
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